CRISPR Therapeutics AG (CRSP) Stock Grade

About CRISPR Therapeutics AG's fundamentals

CRISPR Therapeutics is a $5.2 billion biotechnology company that reported a substantial net loss in its latest annual statement, resulting in a net margin of -16569.8%. Revenue declined sharply by 90% year-over-year, indicating a significant contraction in sales. The company does not pay a dividend, and profitability metrics like P/E ratio and return on equity are not applicable given the loss position. As a pre-commercial or early-stage therapeutic company, CRISPR is characteristic of biotech firms in development phases that prioritize R&D spending over near-term profitability.